200,000+ products from a single source!
sales@angenechem.com
Home > Indoles and Oxindole > 289483-69-8
289483-69-8 | Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)-
CAS No: 289483-69-8 Catalog No: AG002X5N MDL No:
Product Description
Catalog Number:
AG002X5N
Chemical Name:
Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)-
CAS Number:
289483-69-8
Molecular Formula:
C17H12N4O2S
Molecular Weight:
336.3678
IUPAC Name:
3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)benzenesulfonamide
InChI:
InChI=1S/C17H12N4O2S/c1-11-5-6-15(17-16(11)13(9-19)10-20-17)21-24(22,23)14-4-2-3-12(7-14)8-18/h2-7,10,20-21H,1H3
InChI Key:
LWGUASZLXHYWIV-UHFFFAOYSA-N
SMILES:
N#Cc1cccc(c1)S(=O)(=O)Nc1ccc(c2c1[nH]cc2C#N)C
UNII:
TVH5K7949N
NSC Number:
719239
Properties
Complexity:
668
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
336.068g/mol
Formal Charge:
0
Heavy Atom Count:
24
Hydrogen Bond Acceptor Count:
5
Hydrogen Bond Donor Count:
2
Isotope Atom Count:
0
Molecular Weight:
336.369g/mol
Monoisotopic Mass:
336.068g/mol
Rotatable Bond Count:
3
Topological Polar Surface Area:
118A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
2.4
Literature
| Title | Journal |
|---|---|
| Evaluation of α2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies. | The AAPS journal 20110601 |
| Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110101 |
| Small molecule integrin antagonists in cancer therapy. | Mini reviews in medicinal chemistry 20091001 |
| Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820. | Investigational new drugs 20090401 |
| Integrins: molecular targets in cancer therapy. | Current oncology reports 20060301 |
| An angiogenesis inhibitor E7820 shows broad-spectrum tumor growth inhibition in a xenograft model: possible value of integrin alpha2 on platelets as a biological marker. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040215 |
| Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. | Cancer research 20021101 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.